Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMedOpen access

Adipose-derived mesenchymal stromal cell-microenvironment interaction network in metabolic syndrome: ADMSC injury response, adaptive regulation, and regenerative potential.

Yuan LY., Yuan QY., Guo DW., Tan HL., Guan XH.

Narrative Review on Type 2 Diabetes, Chronic Inflammation, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Cell Dev Biol (2026)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
42181689
PMCID
PMC13189907
DOI
10.3389/fcell.2026.1821763

Abstract (original English)

Metabolic syndrome (MetS) is a complex metabolic disorder characterized by insulin resistance, central obesity, dyslipidemia, hypertension, and chronic inflammation, which collectively increase the risk of type 2 diabetes mellitus, cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease. Although adipose-derived mesenchymal stromal cells (ADMSCs) have shown promising therapeutic potential in preclinical studies, their efficacy is substantially influenced by the diseased local microenvironment. Accumulating evidence indicates that ADMSCs exert multi-target therapeutic effects in MetS by alleviating insulin resistance, modulating inflammation, restoring mitochondrial and redox homeostasis, regulating lipid metabolism, and protecting vascular and metabolic organ function. However, the pathological state associated with MetS, characterized by chronic inflammation, oxidative stress, and metabolic imbalance, can reciprocally impair ADMSC function and limit their therapeutic efficacy. In this review, we summarize the current mechanistic understanding of ADMSC-based therapy for MetS and highlight the bidirectional interaction between ADMSCs and the local microenvironment network, discussing how exosome-based and microenvironment-oriented strategies may support the development of more precise and effective regenerative interventions for metabolic disease.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research